PMID- 36708976
OWN - NLM
STAT- MEDLINE
DCOM- 20230214
LR  - 20230214
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 942
DP  - 2023 Mar 5
TI  - Myricetin ameliorates experimental autoimmune myocarditis in mice by modulating 
      immune response and inhibiting MCP-1 expression.
PG  - 175549
LID - S0014-2999(23)00060-2 [pii]
LID - 10.1016/j.ejphar.2023.175549 [doi]
AB  - Myocarditis is defined as an inflammatory disease of the myocardium, and the 
      autoimmune response specific to myocardium plays an important role in chronic 
      myocarditis. Inhibiting myocardial-specific autoimmune response and inflammation 
      is crucial to treat myocarditis. Myricetin is a plant-derived flavonoid in nature 
      which has potent anti-inflammatory and cardiovascular protective properties. 
      However, the pharmacological effect of myricetin in autoimmune myocarditis is 
      undefined. It is necessary to investigate the role and potential mechanisms of 
      myricetin in autoimmune myocarditis. Therefore, purified cardiac myosin was 
      subcutaneously injected to mice to establish the experimental autoimmune 
      myocarditis (EAM) model. Myricetin was solubilized in normal saline and 
      administered everyday by gavage from the day of immunization. After 21 days of 
      treatment, it was found that myricetin significantly alleviated myocardial injury 
      in EAM mice. The serum anti-cardiac myosin antibody, immunoglobulin (Ig) G, IgM 
      levels and the proportion of T helper 17 (Th17) cells were decreased and the 
      proportion of regulatory T (Treg) cells was increased with the treatment of 
      myricetin in EAM mice. The myosin-specific T cell proliferation was inhibited by 
      myricetin. Meanwhile, myricetin suppressed the expressions of monocyte 
      chemoattractant protein-1 (MCP-1), phospho (p)-p65, p-c-Jun and Act1/TRAF6/TAK1 
      in H9C2 cells and myocardial tissues of EAM mice. These results revealed that 
      myricetin inhibited the autoimmune response specific to myocardium and the 
      expression of MCP-1 in cardiomyocytes, which suggested that myricetin ameliorated 
      autoimmune myocarditis by modulating immune response and the expression of MCP-1. 
      Therefore, myricetin may be a promising therapeutic strategy for autoimmune 
      myocarditis.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Nie, Na
AU  - Nie N
AD  - Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, The 
      First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
FAU - Li, Zhuolun
AU  - Li Z
AD  - Henan Engineering Research Center of Clinical Mass Spectrometry for Precision 
      Medicine, Department of Pharmacy, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, 450052, China.
FAU - Li, Wenhuan
AU  - Li W
AD  - BGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou 
      University, Zhengzhou, 450052, China.
FAU - Huang, Xiao
AU  - Huang X
AD  - Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, The 
      First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
FAU - Jiang, Zuli
AU  - Jiang Z
AD  - Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, The 
      First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
FAU - Shen, Yan
AU  - Shen Y
AD  - Department of Clinical Laboratory, Key Clinical Laboratory of Henan Province, The 
      First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. 
      Electronic address: shenyan62687@126.com.
LA  - eng
PT  - Journal Article
DEP - 20230125
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Chemokine CCL2)
RN  - 0 (Flavonoids)
RN  - EC 3.6.4.1 (Myosins)
RN  - 76XC01FTOJ (myricetin)
RN  - 0 (Ccl2 protein, mouse)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Autoimmune Diseases/drug therapy
MH  - Chemokine CCL2/metabolism
MH  - Disease Models, Animal
MH  - Flavonoids/pharmacology/therapeutic use/metabolism
MH  - Immunity
MH  - *Myocarditis/drug therapy/metabolism
MH  - Myocardium/metabolism
MH  - Myosins/metabolism
OTO - NOTNLM
OT  - Act1/ TRAF6/ TAK1 pathway
OT  - Autoimmune myocarditis
OT  - Immune response
OT  - Monocyte chemoattractant protein-1
OT  - Myricetin
COIS- Declaration of competing interest The authors declare that they have no conflicts 
      of interest in relation to the contents of this article.
EDAT- 2023/01/29 06:00
MHDA- 2023/02/14 06:00
CRDT- 2023/01/28 19:27
PHST- 2022/09/06 00:00 [received]
PHST- 2023/01/24 00:00 [revised]
PHST- 2023/01/24 00:00 [accepted]
PHST- 2023/01/29 06:00 [pubmed]
PHST- 2023/02/14 06:00 [medline]
PHST- 2023/01/28 19:27 [entrez]
AID - S0014-2999(23)00060-2 [pii]
AID - 10.1016/j.ejphar.2023.175549 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2023 Mar 5;942:175549. doi: 10.1016/j.ejphar.2023.175549. Epub 
      2023 Jan 25.